Do analysts prefer CARM or EVGN?

Carisma Therapeutics presently has a consensus target price of $1.00, indicating a potential upside of 12,245.68%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Carisma Therapeutics is more favorable than Evogene. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Do analysts rate UPC or CARM?

Carisma Therapeutics has a consensus price target of $1.00, suggesting a potential upside of 12,245.68%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Carisma Therapeutics is more favorable than Universe Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Universe Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Which has stronger valuation & earnings, UPC or CARM?

Universe Pharmaceuticals has higher revenue and earnings than Carisma Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Universe Pharmaceuticals $17.86M 0.09 -$3.67M N/A N/A Carisma Therapeutics $10.77M 0.03 -$60.48M $0.73 0.01

Is UPC or CARM more profitable?

Universe Pharmaceuticals has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Company Net Margins Return on Equity Return on Assets Universe Pharmaceuticals N/A N/A N/A Carisma Therapeutics -254.28% N/A -192.17%

Do analysts prefer CARM or ITRM?

Carisma Therapeutics presently has a consensus price target of $1.00, indicating a potential upside of 12,245.68%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Carisma Therapeutics is more favorable than Iterum Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is CARM or ITRM more profitable?

Iterum Therapeutics has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Company Net Margins Return on Equity Return on Assets Carisma Therapeutics -254.28% N/A -192.17% Iterum Therapeutics N/A N/A -65.54%

Do analysts prefer JAGX or CARM?

Carisma Therapeutics has a consensus price target of $1.00, indicating a potential upside of 12,245.68%. Given Carisma Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Carisma Therapeutics is more favorable than Jaguar Animal Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jaguar Animal Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Carisma Therapeutics (CARM) Competitors

$0.0081 0.00 (0.00%)

As of 06/26/2026 02:58 PM Eastern

Compare

CARM vs. EVGN, UPC, ITRM, PPBT, and JAGX

Should you buy Carisma Therapeutics stock or one of its competitors? MarketBeat compares Carisma Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Carisma Therapeutics include Evogene (EVGN), Universe Pharmaceuticals (UPC), Iterum Therapeutics (ITRM), Purple Biotech (PPBT), and Jaguar Animal Health (JAGX). These companies are all part of the "medical" sector.

How does Carisma Therapeutics compare to Evogene?

Carisma Therapeutics (NASDAQ:CARM) and Evogene (NASDAQ:EVGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Carisma Therapeutics has a net margin of -254.28% compared to Evogene's net margin of -638.12%. Carisma Therapeutics' return on equity of 0.00% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carisma Therapeutics	-254.28%	N/A	-192.17%
Evogene	-638.12%	-158.82%	-80.37%

Evogene has lower revenue, but higher earnings than Carisma Therapeutics. Evogene is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carisma Therapeutics	$10.77M	0.03	-$60.48M	$0.73	0.01
Evogene	$3.85M	0.89	-$8.48M	-$1.39	N/A

Carisma Therapeutics has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market. Comparatively, Evogene has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market.

In the previous week, Evogene had 3 more articles in the media than Carisma Therapeutics. MarketBeat recorded 3 mentions for Evogene and 0 mentions for Carisma Therapeutics. Evogene's average media sentiment score of 0.29 beat Carisma Therapeutics' score of 0.00 indicating that Evogene is being referred to more favorably in the news media.

Company	Overall Sentiment
Carisma Therapeutics	Neutral
Evogene	Neutral

Carisma Therapeutics presently has a consensus target price of $1.00, indicating a potential upside of 12,245.68%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Carisma Therapeutics is more favorable than Evogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 10.4% of Evogene shares are owned by institutional investors. 6.9% of Carisma Therapeutics shares are owned by insiders. Comparatively, 7.4% of Evogene shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Carisma Therapeutics beats Evogene on 9 of the 16 factors compared between the two stocks.

How does Carisma Therapeutics compare to Universe Pharmaceuticals?

Universe Pharmaceuticals (NASDAQ:UPC) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

Carisma Therapeutics has a consensus price target of $1.00, suggesting a potential upside of 12,245.68%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Carisma Therapeutics is more favorable than Universe Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Universe Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Universe Pharmaceuticals had 5 more articles in the media than Carisma Therapeutics. MarketBeat recorded 5 mentions for Universe Pharmaceuticals and 0 mentions for Carisma Therapeutics. Universe Pharmaceuticals' average media sentiment score of 0.71 beat Carisma Therapeutics' score of 0.00 indicating that Universe Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Universe Pharmaceuticals	Positive
Carisma Therapeutics	Neutral

0.2% of Universe Pharmaceuticals shares are held by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are held by institutional investors. 57.4% of Universe Pharmaceuticals shares are held by company insiders. Comparatively, 6.9% of Carisma Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Universe Pharmaceuticals has higher revenue and earnings than Carisma Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Universe Pharmaceuticals	$17.86M	0.09	-$3.67M	N/A	N/A
Carisma Therapeutics	$10.77M	0.03	-$60.48M	$0.73	0.01

Universe Pharmaceuticals has a beta of 1.6, suggesting that its stock price is 60% more volatile than the broader market. Comparatively, Carisma Therapeutics has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market.

Universe Pharmaceuticals has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%.

Company	Net Margins	Return on Equity	Return on Assets
Universe Pharmaceuticals	N/A	N/A	N/A
Carisma Therapeutics	-254.28%	N/A	-192.17%

Summary

Universe Pharmaceuticals beats Carisma Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Carisma Therapeutics compare to Iterum Therapeutics?

Carisma Therapeutics (NASDAQ:CARM) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

Carisma Therapeutics has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market. Comparatively, Iterum Therapeutics has a beta of 2.96, suggesting that its share price is 196% more volatile than the broader market.

Iterum Therapeutics has lower revenue, but higher earnings than Carisma Therapeutics. Iterum Therapeutics is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carisma Therapeutics	$10.77M	0.03	-$60.48M	$0.73	0.01
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A

In the previous week, Iterum Therapeutics had 1 more articles in the media than Carisma Therapeutics. MarketBeat recorded 1 mentions for Iterum Therapeutics and 0 mentions for Carisma Therapeutics. Carisma Therapeutics' average media sentiment score of 0.00 equaled Iterum Therapeutics'average media sentiment score.

Company	Overall Sentiment
Carisma Therapeutics	Neutral
Iterum Therapeutics	Neutral

44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are owned by institutional investors. 6.9% of Carisma Therapeutics shares are owned by insiders. Comparatively, 2.0% of Iterum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Iterum Therapeutics has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%.

Company	Net Margins	Return on Equity	Return on Assets
Carisma Therapeutics	-254.28%	N/A	-192.17%
Iterum Therapeutics	N/A	N/A	-65.54%

Carisma Therapeutics presently has a consensus price target of $1.00, indicating a potential upside of 12,245.68%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Carisma Therapeutics is more favorable than Iterum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Carisma Therapeutics beats Iterum Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Carisma Therapeutics compare to Purple Biotech?

Purple Biotech (NASDAQ:PPBT) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.

In the previous week, Purple Biotech had 2 more articles in the media than Carisma Therapeutics. MarketBeat recorded 2 mentions for Purple Biotech and 0 mentions for Carisma Therapeutics. Purple Biotech's average media sentiment score of 0.43 beat Carisma Therapeutics' score of 0.00 indicating that Purple Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Purple Biotech	Neutral
Carisma Therapeutics	Neutral

Purple Biotech has higher earnings, but lower revenue than Carisma Therapeutics. Purple Biotech is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Purple Biotech	N/A	N/A	-$26.39M	-$18.84	N/A
Carisma Therapeutics	$10.77M	0.03	-$60.48M	$0.73	0.01

Purple Biotech currently has a consensus price target of $30.00, suggesting a potential upside of 1,685.71%. Carisma Therapeutics has a consensus price target of $1.00, suggesting a potential upside of 12,245.68%. Given Carisma Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Carisma Therapeutics is more favorable than Purple Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

9.6% of Purple Biotech shares are owned by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are owned by institutional investors. 3.0% of Purple Biotech shares are owned by company insiders. Comparatively, 6.9% of Carisma Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Purple Biotech has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Purple Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Purple Biotech	N/A	-123.63%	-98.72%
Carisma Therapeutics	-254.28%	N/A	-192.17%

Purple Biotech has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Carisma Therapeutics has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market.

Summary

Carisma Therapeutics beats Purple Biotech on 10 of the 15 factors compared between the two stocks.

How does Carisma Therapeutics compare to Jaguar Animal Health?

Jaguar Animal Health (NASDAQ:JAGX) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

Jaguar Animal Health has a beta of -0.09, suggesting that its stock price is 109% less volatile than the broader market. Comparatively, Carisma Therapeutics has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market.

Jaguar Animal Health has a net margin of -169.04% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Jaguar Animal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jaguar Animal Health	-169.04%	-1,194.94%	-115.55%
Carisma Therapeutics	-254.28%	N/A	-192.17%

12.0% of Jaguar Animal Health shares are owned by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are owned by institutional investors. 2.0% of Jaguar Animal Health shares are owned by insiders. Comparatively, 6.9% of Carisma Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Jaguar Animal Health had 1 more articles in the media than Carisma Therapeutics. MarketBeat recorded 1 mentions for Jaguar Animal Health and 0 mentions for Carisma Therapeutics. Jaguar Animal Health's average media sentiment score of 0.63 beat Carisma Therapeutics' score of 0.00 indicating that Jaguar Animal Health is being referred to more favorably in the media.

Company	Overall Sentiment
Jaguar Animal Health	Positive
Carisma Therapeutics	Neutral

Jaguar Animal Health has higher revenue and earnings than Carisma Therapeutics. Jaguar Animal Health is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jaguar Animal Health	$11.51M	0.16	-$53.43M	-$591.92	N/A
Carisma Therapeutics	$10.77M	0.03	-$60.48M	$0.73	0.01

Carisma Therapeutics has a consensus price target of $1.00, indicating a potential upside of 12,245.68%. Given Carisma Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Carisma Therapeutics is more favorable than Jaguar Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jaguar Animal Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

Carisma Therapeutics beats Jaguar Animal Health on 10 of the 17 factors compared between the two stocks.

Get Carisma Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CARM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CARM vs. The Competition

Export

Metric	Carisma Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$339K	$3.01B	$6.70B	$12.22B
Dividend Yield	N/A	1.77%	2.67%	6.13%
P/E Ratio	0.01	19.54	25.79	24.18
Price / Sales	0.03	337.84	560.49	109.71
Price / Cash	N/A	56.66	46.99	54.37
Price / Book	-0.01	4.21	10.77	6.35
Net Income	-$60.48M	$64.45M	$3.57B	$337.74M
7 Day Performance	N/A	2.22%	2.18%	0.09%
1 Month Performance	N/A	1.36%	1.09%	-0.13%
1 Year Performance	N/A	29.73%	34.22%	27.58%

Carisma Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CARM Carisma Therapeutics	2.5376 of 5 stars	$0.01 flat	$1.00 +12,245.7%	-98.0%	$339K	$10.77M	0.01	20
EVGN Evogene	0.9956 of 5 stars	$0.49 -1.6%	N/A	-69.3%	$4.35M	$3.85M	N/A	140	Short Interest Increase
UPC Universe Pharmaceuticals	1.0641 of 5 stars	$3.04 +6.7%	N/A	-21.9%	$1.61M	$17.86M	N/A	220	News Coverage Gap Down
ITRM Iterum Therapeutics	0.0382 of 5 stars	$0.03 flat	N/A	N/A	$1.60M	$390K	N/A	10	News Coverage
PPBT Purple Biotech	2.4113 of 5 stars	$1.77 +4.1%	$30.00 +1,594.9%	-92.7%	$1.58M	N/A	N/A	20	Short Interest Increase Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CARM) was last updated on 6/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Carisma Therapeutics (CARM) Competitors

CARM vs. EVGN, UPC, ITRM, PPBT, and JAGX

How does Carisma Therapeutics compare to Evogene?

Summary

How does Carisma Therapeutics compare to Universe Pharmaceuticals?

Summary

How does Carisma Therapeutics compare to Iterum Therapeutics?

Summary

How does Carisma Therapeutics compare to Purple Biotech?

Summary

How does Carisma Therapeutics compare to Jaguar Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CARM vs. The Competition

Carisma Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Carisma Therapeutics (CARM) Competitors

CARM vs. EVGN, UPC, ITRM, PPBT, and JAGX

How does Carisma Therapeutics compare to Evogene?

Is CARM or EVGN more profitable?

Which has better valuation & earnings, CARM or EVGN?

Which has more risk and volatility, CARM or EVGN?

Does the media prefer CARM or EVGN?

Do analysts prefer CARM or EVGN?

Do institutionals and insiders believe in CARM or EVGN?

Summary

How does Carisma Therapeutics compare to Universe Pharmaceuticals?

Do analysts rate UPC or CARM?

Does the media refer more to UPC or CARM?

Do institutionals & insiders hold more shares of UPC or CARM?

Which has stronger valuation & earnings, UPC or CARM?

Which has more risk & volatility, UPC or CARM?

Is UPC or CARM more profitable?

Summary

How does Carisma Therapeutics compare to Iterum Therapeutics?

Which has more risk & volatility, CARM or ITRM?

Which has preferable earnings and valuation, CARM or ITRM?

Does the media prefer CARM or ITRM?

Do institutionals and insiders believe in CARM or ITRM?

Is CARM or ITRM more profitable?

Do analysts prefer CARM or ITRM?

Summary

How does Carisma Therapeutics compare to Purple Biotech?

Does the media favor PPBT or CARM?

Which has higher valuation & earnings, PPBT or CARM?

Do analysts prefer PPBT or CARM?

Do insiders and institutionals hold more shares of PPBT or CARM?

Is PPBT or CARM more profitable?

Which has more volatility & risk, PPBT or CARM?

Summary

How does Carisma Therapeutics compare to Jaguar Animal Health?

Which has more volatility and risk, JAGX or CARM?

Is JAGX or CARM more profitable?

Do institutionals and insiders believe in JAGX or CARM?

Does the media prefer JAGX or CARM?

Which has better earnings & valuation, JAGX or CARM?

Do analysts prefer JAGX or CARM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CARM vs. The Competition

Carisma Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools